Vespyr Brands is proud to announce the expansion of the Cold-EEZE® brand's claim, "Clinically tested to shorten colds by 42%," to its entire range of lozenges. This significant development follows a comprehensive clinical study, which demonstrated the effectiveness of the Cold-EEZE Zinc Lozenge formula in reducing the duration of common colds.

The study, conducted at the Cleveland Clinic and published in a peer-reviewed journal, found that Cold-EEZE® lozenges, when taken at the first sign of a cold and used as directed, can reduce the length of colds by 42%. The active ingredient, Zinc Gluconate, works by releasing zinc ions in the mouth, which inhibit the cold virus's ability to replicate.

This broader claim now includes all varieties of Cold-EEZE® lozenges, such as the Plus Defense and Plus Cold &Flu Symptom Relief lines. This emphasizes the brand's dedication to offering scientifically proven, effective remedies for cold relief. The company's commitment to health and wellness is underscored by its thorough testing and validation processes, which guarantee that customers get top-quality care during the cold season.

Formore information on the clinical study and the Cold-EEZE® lozenge range, visit:

https://coldeeze.com/pages/clinical-study